Document and Entity Information	6 Months Ended
Document and Entity Information	Jun. 30, 2015	Jul. 29, 2015
Document Documentand Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q2
Trading Symbol	iart
Entity Registrant Name	INTEGRA LIFESCIENCES HOLDINGS CORP
Entity Central Index Key	0000917520
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		33,163,415

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (UNAUDITED) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Statement [Abstract]
Total revenue, net	$ 244,078	$ 231,351	$ 477,743	$ 446,410
Costs and expenses:
Cost of goods sold	86,539	86,976	173,261	169,359
Research and development	13,891	13,745	26,447	26,312
Selling, general and administrative	126,590	115,253	240,654	223,591
Intangible asset amortization	3,104	2,985	6,639	6,018
Total costs and expenses	230,124	218,959	447,001	425,280
Operating income	13,954	12,392	30,742	21,130
Interest income	8	58	13	120
Interest expense	(5,471)	(5,382)	(10,963)	(10,524)
Other (expense) income, net	(919)	118	397	435
Income before income taxes	7,572	7,186	20,189	11,161
Income tax expense	2,574	2,361	6,807	4,130
Net income	4,998	4,825	13,382	7,031
Basic net income per common share (in dollars per share)	$ 0.15	$ 0.15	$ 0.41	$ 0.22
Diluted net income per common share (in dollars per share)	$ 0.15	$ 0.15	$ 0.40	$ 0.21
Weighted average common shares outstanding (See Note 10):
Basic (in shares)	33,032	32,398	32,884	32,336
Diluted (in shares)	33,939	32,804	33,644	32,796
Comprehensive income (loss) (See Note 11)	$ 12,325	$ 4,752	$ (3,418)	$ 7,957

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 131,296	$ 71,994
Trade accounts receivable, net of allowances of $6,447 and $6,184	134,546	131,918
Inventories, net	241,835	237,114
Deferred tax assets	58,173	58,663
Prepaid expenses and other current assets	42,397	29,632
Total current assets	608,247	529,321
Property, plant and equipment, net	215,460	209,986
Intangible assets, net	440,583	459,459
Goodwill	357,022	363,888
Deferred tax assets	5,689	5,603
Other assets	10,893	10,368
Total assets	1,637,894	1,578,625
Current liabilities:
Borrowings under senior credit facility	7,500	3,750
Convertible securities	2,903	0
Accounts payable, trade	58,197	34,060
Deferred revenue	4,303	5,176
Accrued compensation	40,019	40,943
Accrued expenses and other current liabilities	42,831	42,096
Total current liabilities	155,753	126,025
Long-term borrowings under senior credit facility	429,375	413,125
Long-term convertible securities	214,358	213,121
Deferred tax liabilities	94,701	91,623
Other liabilities	31,984	30,409
Total liabilities	926,171	874,303
Commitments and contingencies
Stockholders’ equity:
Preferred stock; no par value; 15,000 authorized shares; none outstanding	0	0
Common stock; $0.01 par value; 60,000 authorized shares; 42,012 and 41,644 issued at June 30, 2015 and December 31, 2014, respectively	420	416
Additional paid-in capital	790,371	779,555
Treasury stock, at cost; 8,903 shares at June 30, 2015 and December 31, 2014	(367,121)	(367,121)
Accumulated other comprehensive loss	(40,288)	(23,488)
Retained earnings	328,341	314,960
Total stockholders’ equity	711,723	704,322
Total liabilities and stockholders’ equity	$ 1,637,894	$ 1,578,625

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) (USD $) In Thousands, except Share data, unless otherwise specified	Jun. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Trade accounts receivable, allowances	$ 6,447	$ 6,184
Preferred Stock, par value (in dollars per share)	$ 0	$ 0
Preferred Stock, authorized shares (in shares)	15,000,000	15,000,000
Preferred Stock, outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	60,000,000	60,000,000
Common stock, shares issued (in shares)	42,012,000	41,644,000
Treasury stock, shares (in shares)	8,903,000	8,903,000

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
OPERATING ACTIVITIES:
Net income	$ 13,382	$ 7,031
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	31,159	29,164
Non-cash impairment charges	409	600
Deferred income tax	1,648	(503)
Amortization of debt issuance costs	1,060	1,243
Non-cash interest expense	3,744	3,433
Loss on disposal of property and equipment	38	378
Change in fair value of contingent consideration	239	(998)
Share-based compensation	5,616	8,302
Excess tax benefits from stock-based compensation arrangements	(3,501)	(1,164)
Changes in assets and liabilities, net of business acquisitions:
Accounts receivable	(4,480)	106
Inventories	(9,875)	(17,367)
Prepaid expenses and other current assets	(7,314)	(2,832)
Other non-current assets	(1,806)	(1,846)
Accounts payable, accrued expenses and other current liabilities	19,613	4,848
Deferred revenue	(805)	188
Other non-current liabilities	615	(2,952)
Net cash provided by operating activities	49,742	27,631
INVESTING ACTIVITIES:
Purchases of property and equipment	(22,013)	(20,691)
Sale of property and equipment	1,438	0
Cash used in business acquisition, net of cash acquired	0	(235,000)
Proceeds from working capital purchase price adjustment	1,831	0
Net cash used in investing activities	(18,744)	(255,691)
FINANCING ACTIVITIES:
Borrowings under senior credit facility	35,000	235,000
Repayments under senior credit facility	(15,000)	0
Principal payments under capital lease obligations	(396)	(245)
Proceeds from exercised stock options	7,345	8,317
Excess tax benefits from stock-based compensation arrangements	3,501	1,164
Net cash provided by financing activities	30,450	244,236
Effect of exchange rate changes on cash and cash equivalents	(2,146)	370
Net change in cash and cash equivalents	59,302	16,546
Cash and cash equivalents at beginning of period	71,994	120,614
Cash and cash equivalents at end of period	$ 131,296	$ 137,160

BASIS OF PRESENTATION	6 Months Ended
BASIS OF PRESENTATION	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION General The terms “we,” “our,” “us,” “Company” and “Integra” refer to Integra LifeSciences Holdings Corporation, a Delaware corporation, and its subsidiaries unless the context suggests otherwise. In the opinion of management, the June 30, 2015 unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position, results of operations and cash flows of the Company. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the year ended December 31, 2014 included in the Company’s Annual Report on Form 10-K. The December 31, 2014 consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States. Operating results for the three- and six-month periods ended June 30, 2015 are not necessarily indicative of the results to be expected for the entire year. The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenues and expenses. Significant estimates affecting amounts reported or disclosed in the consolidated financial statements include allowances for doubtful accounts receivable and sales returns and allowances, net realizable value of inventories, valuation of intangible assets including in-process research and development, amortization periods for acquired intangible assets, discount rates and estimated projected cash flows used to value and test impairments of long-lived assets and goodwill, estimates of projected cash flows and depreciation and amortization periods for long-lived assets, computation of taxes, valuation allowances recorded against deferred tax assets, the valuation of stock-based compensation, valuation of pension assets and liabilities, valuation of derivative instruments, valuation of the equity component of convertible debt instruments, valuation of contingent liabilities, the fair value of debt instruments and loss contingencies. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the current circumstances. Actual results could differ from these estimates. Certain amounts from the prior year’s financial statements have been reclassified in order to conform to the current year’s presentation. Recently Issued Accounting Standards In April 2014, the FASB issued amendments to guidance for reporting discontinued operations and disposals of components of an entity. The amended guidance requires that a disposal representing a strategic shift that has (or will have) a major effect on an entity’s financial results or a business activity classified as held for sale should be reported as discontinued operations. The amendments also expand the disclosure requirements for discontinued operations and add new disclosures for individually significant dispositions that do not qualify as discontinued operations. The amendments are effective prospectively for fiscal years, and interim reporting periods within those years, beginning after December 15, 2014 (early adoption is permitted only for disposals that have not been previously reported). The new guidance is effective for Integra prospectively for all disposals (or classifications as held for sale) of components of an entity that occur after January 1, 2015 and will be in effect for the spin-off of the spine business in the Company's third quarter 2015 results. In May 2014, the FASB issued Update No. 2014-09, Revenue from Contracts with Customers (Topic 606). The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should 1) identify the contract(s) with a customer, 2) identify the performance obligations in the contract, 3) determine the transaction price, 4) allocate the transaction price to the performance obligations in the contract, and 5) recognize revenue when (or as) the entity satisfies a performance obligation. In July 2015, the FASB deferred for one year the effective date of the new revenue standard, but early adoption will be permitted. The new standard will be effective for the Company on January 1, 2018. The Company is in the process of evaluating the impact of this standard on its financial statements. In June 2014, the FASB issued Update No. 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period (Topic 718). The amendments require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Topic 718 as it relates to awards with performance conditions that affect vesting to account for such awards. As such, the performance target should not be reflected in estimating the grant-date fair value of the award. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. If the performance target becomes probable of being achieved before the end of the requisite service period, the remaining unrecognized compensation cost should be recognized prospectively over the remaining requisite service period. The requisite service period ends when the employee can cease rendering service and still be eligible to vest in the award if the performance target is achieved. This update is effective for annual reporting periods beginning after December 15, 2015, including interim periods within that reporting period, and early adoption is permitted. The implementation of the amended guidance is not expected to have a material impact on the consolidated financial position or results of operations. In August 2014, the FASB issued Update No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The amendment requires management to evaluate, for each annual and interim reporting period, whether there are conditions and events, considered in the aggregate, that raise substantial doubt about an entity’s ability to continue as a going concern within one year after the date the financial statements are issued or are available to be issued. If substantial doubt is raised, additional disclosures around management’s plan to alleviate these doubts are required. This update will become effective for all annual periods and interim reporting periods beginning after December 15, 2016. The implementation of the amended guidance is not expected to have an impact on current disclosures in the financial statements. In April 2015, the FASB issued Update No. 2015-03, Simplifying the Presentation of Debt Issuance Costs. The amendment requires that all costs incurred to issue debt be presented in the balance sheet as a direct deduction from the carrying value of the debt. The new standard is limited to the presentation of debt issuance costs and does not affect the recognition or measurement of debt issuance costs. This update will become effective for all annual periods and interim reporting periods beginning after December 15, 2015. The implementation of the amended guidance is not expected to have a material impact on the consolidated results of operations and will result in a reclassification of the debt issuance costs from other long-term assets to long-term debt when adopted. There are no other recently issued accounting pronouncements that are expected to have a material effect on the financial position, results of operations or cash flows.

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References+ Details

BUSINESS ACQUISITIONS

6 Months Ended

Jun. 30, 2015

Business Combinations [Abstract]

BUSINESS ACQUISITIONS

Metasurg

On December 5, 2014, the Company acquired certain assets of Koby Ventures II, L.P. dba Metasurg ("Metasurg") for an aggregate purchase price of $27.6 million (including working capital and purchase price adjustments of $0.4 million). The purchase price consists of an initial cash payment to Metasurg of $26.5 million, a separate purchase price adjustment cash payment of $0.4 million, and contingent consideration with an acquisition date fair value of $0.7 million. The potential maximum undiscounted contingent consideration of $38.5 million is based on reaching certain sales levels for acquired products from April 1, 2015 through June 30, 2016. The fair value of this liability is based on future sales projections of the Metasurg product under various potential scenarios and weighting the probability of these outcomes for the twelve-month period ended December 31, 2015. At the date of the acquisition, the cash flow projection was discounted using an internal rate of return of 19.9%. These fair value measurements were based on significant inputs not observed in the market and thus represented a Level 3 measurement.

Metasurg develops intuitive implant systems for the foot and ankle market and sells almost entirely in the U.S. market. The acquired foot and ankle products will enhance the Company's lower extremities market position.

The Company recorded revenue for Metasurg of approximately $1.7 million and $3.3 million in the condensed consolidated statements of operations for the three- and six-month period ended June 30, 2015. The net income or loss attributable to this acquisition cannot be identified on a stand-alone basis because it has been fully integrated into the Company's operations.

The Company adjusted the preliminary purchase price allocation during the quarter ended June 30, 2015 to reflect the $0.4 million working capital and purchase price adjustment. The following summarizes the preliminary allocation of the purchase price as of June 30, 2015 based on the fair value of the assets acquired and liabilities assumed:



	Preliminary Purchase Price Allocation
	(Dollars in thousands)
Inventory	$	4,800
Property, plant, and equipment	1,246
Intangible assets:			Wtd. Avg. Life:
Technology product rights	20,590		8 - 14 Years
In-process research and development	190		Indefinite
Goodwill	732
Net assets acquired	$	27,558

MicroFrance

On October 27, 2014, the Company acquired all outstanding shares of Medtronic Xomed Instrumentation, SAS ("MicroFrance") from Medtronic, Inc. ("Medtronic") as well as certain assets of Medtronic for $60.1 million in cash (including working capital and purchase price adjustments of $1.5 million, of which $0.8 million was recorded against goodwill). MicroFrance specializes in manual ear, nose, and throat ("ENT") surgical instruments and designs, manufactures, and sells reusable handheld instruments to ENT and laparoscopy surgical specialists around the world. The acquired ENT instruments fill a portfolio gap for the Company with clear growth opportunities through market adjacencies and provides for increased scale and reach in the international market.

The Company recorded revenue for MicroFrance of approximately $6.3 million and $12.1 million in the condensed consolidated statements of operations for the three- and six-month period ended June 30, 2015. The net income or loss attributable to this acquisition cannot be identified on a stand-alone basis because it has been fully integrated into the Company's operations.

The Company adjusted the preliminary purchase price allocation during the quarter ended March 31, 2015 to reflect the $1.5 million working capital and purchase price adjustments. The following summarizes the final allocation of the purchase price as of June 30, 2015 based on the fair value of the assets acquired and liabilities assumed:



	Final Purchase Price Allocation
	(Dollars in thousands)
Cash	$	2,195
Inventory	3,155
Prepaid expenses	620
Property, plant, and equipment	3,675
Other current assets	5,025
Intangible assets:			Wtd. Avg. Life:
Trade name	11,990		20 Years
Technology	4,580		15 - 16 Years
Customer relationships	18,130		12 - 16 Years
Goodwill	16,607
Total assets acquired	65,977
Accounts payable and other liabilities	5,910
Net assets acquired	$	60,067

Confluent Surgical, Inc.

On January 15, 2014, the Company acquired all outstanding shares of Confluent Surgical, Inc., ("Confluent Surgical") - including its surgical sealant and adhesion barrier product lines - from Covidien Group S.a.r.l, ("Covidien") for an aggregate purchase price of $255.9 million. The purchase price consists of an initial cash payment to Covidien of $231.0 million upon the closing of the transaction, a separate prepayment of $4.0 million made under a transitional supply agreement with an affiliate of Covidien, and contingent consideration with an acquisition date fair value of $20.9 million. The potential maximum undiscounted contingent consideration of $30.0 million consists of $25.0 million upon obtaining certain U.S. governmental approvals and $5.0 million upon obtaining certain European governmental approvals, both related to the completion of the transition of the Confluent Surgical business to the Company.

The transitional supply agreement secures the supply of the acquired products from an affiliate of Covidien until the earlier of (i) the time that the transition of the Confluent Surgical business as discussed above is complete, or (ii) the fifth anniversary of the effective date of the agreement (the agreement also contains an option to extend for another two years by providing written notice at least 180 days prior to the end of the initial five-year period). This agreement contains financial incentives to the affiliate of Covidien for the timely supply of products each fiscal quarter through the third anniversary of the agreement. The prices paid under the supply agreement are essentially flat through the third anniversary of the agreement, and then increase significantly each of the following three years. The Company also entered into a transition services agreement with an affiliate of Covidien at the closing for services such as customer service, accounting and information technology management, clinical and regulatory affairs, manufacturing transition services, and other functions.

This acquisition complements the Company's global neurosurgery growth strategy aimed at providing a broader set of solutions for surgical procedures in the head.

The Company recorded revenue for Confluent Surgical of approximately $18.9 million and $36.6 million in the condensed consolidated statements of operations for the three- and six-month periods ended June 30, 2015 and $14.1 million and $32.4 million for the three- and six-month periods ended June 30, 2014. The net income or loss attributable to this acquisition cannot be identified on a stand-alone basis because it has been fully integrated into the Company's operations.

The Company adjusted the preliminary purchase price allocation during the quarter ended June 30, 2014 to reduce deferred tax liabilities by $12.4 million. This adjustment offset goodwill and was the result of the Company analyzing and revising its tax positions in certain jurisdictions. The following summarizes the final allocation of the purchase price as of June 30, 2015 based on the fair value of the assets acquired and liabilities assumed:



	Final Purchase Price Allocation
	(Dollars in thousands)
Inventory deposit	$	4,000
Fixed assets	438
Intangible assets:			Wtd. Avg. Life
Technology product rights	239,800		3 - 20 Years
Other	400		Less than 1 year
Deferred tax assets - long term	12
Goodwill	105,331
Total assets acquired	349,981
Contingent supply liability	5,891
Other	731
Deferred tax liabilities - long term	87,464
Net assets acquired	$	255,895

Subsequent to the acquisition date, a regulatory event occurred that resulted in the full-impairment of one of the acquired technology product rights of $0.6 million. This event was not known, or knowable, at the time of the acquisition and therefore the impairment has been included in the Company's cost of sales.

The Company accounted for the contingent supply liability by recording its fair value as a liability on the date of the acquisition based on a discounted cash-flow model. This contingent supply liability relates to contractual quarterly incentive payments that will be made to an affiliate of Covidien if certain supply minimums under the transitional supply agreement are met.

The Company accounted for the contingent consideration by recording its fair value as a liability on the date of the acquisition. The contingent consideration relates to the Company's obtaining certain U.S. and European regulatory approvals. At the date of the acquisition, both of these milestones were valued using a discount rate of 2.2%, which is equivalent to the cost of debt for the estimated time horizon, and an overall probability of occurring of 95%. Accordingly, on January 15, 2014 the Company recorded a $20.9 million liability representing the initial fair value estimate of the probability weighted contingent consideration that management believes will be paid between early 2017 and late 2018. Depending on the expected timing of the estimated payments, the acquisition date fair value of the probability adjusted payments could have been $0.3 million higher or $0.4 million lower. These fair value measurements were based on significant inputs not observed in the market and thus represented a Level 3 measurement. The contingent consideration is re-measured to fair value at each reporting date until the contingency is resolved, and those changes in fair value are recognized in earnings.

The goodwill recorded in connection with these acquisitions is based on (i) expected cost savings, operating synergies and other benefits expected to result from the combined operations, (ii) the value of the going-concern element of the existing businesses (that is, the higher rate of return on the assembled net assets versus if the Company had acquired all of the net assets separately), and (iii) intangible assets that do not qualify for separate recognition such as an assembled workforce. The acquisitions generated a combination of deductible and non-deductible goodwill.

Contingent consideration

The Company increased the fair value of contingent consideration during the six-month period ended June 30, 2015 to reflect the change in the time value of money during the period. A reconciliation of the opening balances to the closing balances of these Level 3 measurements is as follows (in thousands):



			Location in Statement of Operations
Balance as of January 1, 2015	$	22,008
Loss from increase in fair value of contingent consideration liabilities	239		Selling, general and administrative
Fair value at June 30, 2015	$	22,247

The entire contingent consideration balance was included in Other liabilities at June 30, 2015 and December 31, 2014.

Pro Forma Results

The following unaudited pro forma financial information summarizes the results of operations for the three and six months ended June 30, 2014 as if the acquisitions completed by the Company during 2014 had been completed as of January 1, 2013. The pro forma results are based upon certain assumptions and estimates, and they give effect to actual operating results prior to the acquisition and adjustments to reflect (i) the change in interest expense, depreciation expense, and intangible asset amortization, (ii) certain external expenses related to the acquisition as if they were incurred on January 1, 2013 that will not be recurring in the post-acquisition periods, and (iii) income taxes on the aforementioned adjustments at the Company’s statutory rate. No effect has been given to other cost reductions or operating synergies. As a result, these pro forma results do not necessarily represent results that would have occurred if the acquisition had taken place on the basis assumed above, nor are they indicative of the results of future combined operations.



	Three Months Ended June 30, 2014		Six Months Ended June 30, 2014
	(In thousands, except per share amounts)
Total revenue	$	241,801	$	467,310
Net income	$	7,009	$	12,581
Net income per share:
Basic	$	0.22	$	0.39

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4922-128472

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4926-128472

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4934-128472

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1383-128463

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1486-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1497-128463

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1490-128463

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1500-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1524-128463

+ Details

INVENTORIES

6 Months Ended

Jun. 30, 2015

Inventory, Net [Abstract]

INVENTORIES

Inventories, net consisted of the following:



	June 30, 2015		December 31, 2014
	(In thousands)
Finished goods	$	146,912	$	150,483
Work in process	54,707		50,166
Raw materials	40,216		36,465
	$	241,835	$	237,114

- Definition

The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.

+ References+ Details

GOODWILL AND OTHER INTANGIBLE ASSETS

6 Months Ended

Jun. 30, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND OTHER INTANGIBLE ASSETS

In the first quarter of 2015 the Company revised its reportable segments in connection with the realignment of its portfolio. Specifically, the Company integrated the five existing business divisions into three global divisions, no longer focusing on international as a separate reportable segment but managing each business globally. The change in reportable segments resulted in the Company's requirement to reallocate existing goodwill to the new reportable segments based on the relative-fair-value of the Company's four underlying reporting units. With the reportable segments now being managed at a global level, goodwill previously assigned to the EMEA, LAPAC, and Private Label reporting units was reallocated to the new global reporting units. The Company estimated the fair value of the reporting units using a discounted cash flow model, which incorporates significant estimates and assumptions made by management which, by their nature, are characterized by uncertainty. Inputs used to fair value the Company's reporting units are considered inputs of the fair value hierarchy. For Level 3 measurements, significant increases or decreases in long-term growth rates or discount rates in isolation or in combination could result in a significantly lower or higher fair value measurement. The key assumptions impacting the valuation included the following:


•	The reporting unit's financial projections, which are based on management's assessment of regional and macroeconomic variables, industry trends and market opportunities, and the Company's strategic objectives and future growth plans.

•

The projected terminal value for the reporting unit, which represents the present value of projected cash flows beyond the last period in the discounted cash flow analysis. The terminal value reflects the Company's assumptions related to long-term growth rates and profitability, which are based on several factors, including local and macroeconomic variables, market opportunities, and future growth plans.

•

The discount rate used to measure the present value of the projected future cash flows is set using a weighted-average cost of capital method that considers market and industry data as well as the Company's specific risk factors that are likely to be considered by a market participant. The weighted-average cost of capital is the Company's estimate of the overall after-tax rate of return required by equity and debt holders of a business enterprise.

Based on the Company's fair value calculations, with the exception of the Spine reporting unit, given the excess of the Specialty Surgical Solutions Instruments, Specialty Surgical Solutions Neurosurgery, and Orthopedics and Tissue Technologies estimated fair value over their carrying value after the reallocation of goodwill, management concluded that any future goodwill impairment is not likely. The Company's allocation of goodwill to the Spine reporting unit has been impaired during the first quarter of 2015 as a result of the carrying value of its goodwill exceeding the implied fair value. Refer to Note 12 - Segment and Geographic Information for more information on the change in reportable segments.

Changes in the carrying amount of goodwill for the six months ended June 30, 2015 were as follows:



	Specialty Surgical Solutions			Orthopedics and Tissue Technologies			Spine			Total
	(In thousands)
Goodwill, gross	$	281,829		$	81,650		$	409		$	363,888
Accumulated impairment losses	—			—			—			—
Goodwill at December 31, 2014	281,829			81,650			409			363,888
MicroFrance working capital and purchase price adjustments	(828		)	—			—			(828		)
Metasurg working capital and purchase price adjustment	—			263			—			263
Goodwill impairment charge	—			—			(409		)	(409		)
Foreign currency translation	(4,451		)	(1,441		)	—			(5,892		)
Balance, June 30, 2015	$	276,550		$	80,472		$	—		$	357,022

The components of the Company’s identifiable intangible assets were as follows:



	June 30, 2015
	Weighted Average Life	Cost		Accumulated Amortization			Net
	(Dollars in thousands)
Completed technology	18 years	$	344,406	$	(72,393	)	$	272,013
Customer relationships	12 years	159,548		(91,621		)	67,927
Trademarks/brand names	34 years	43,221		(15,814		)	27,407
Trademarks/brand names	Indefinite	48,484		—			48,484
Supplier relationships	27 years	34,721		(11,522		)	23,199
All other⁽¹⁾	4 years	2,721		(1,168		)	1,553
		$	633,101	$	(192,518	)	$	440,583



	December 31, 2014
	Weighted Average Life	Cost		Accumulated Amortization			Net
	(Dollars in thousands)
Completed technology	18 years	$	345,082	$	(62,920	)	$	282,162
Customer relationships	12 years	162,031		(87,653		)	74,378
Trademarks/brand names	34 years	44,520		(15,755		)	28,765
Trademarks/brand names	Indefinite	48,484		—			48,484
Supplier relationships	27 years	34,721		(10,809		)	23,912
All other⁽¹⁾	4 years	4,810		(3,052		)	1,758
		$	639,648	$	(180,189	)	$	459,459


⁽¹⁾	At June 30, 2015 and December 31, 2014, all other included in-process research and development ("IPR&D") of $1.4 million in both periods, which was indefinite-lived.

During the six months ended June 30, 2014, the Company recorded an impairment charge of $0.6 million in cost of goods sold related to technology assets acquired from Confluent Surgical that will no longer be sold resulting from a regulatory event that occurred after the acquisition date.

Based on quarter-end exchange rates, annual amortization expense (including amounts reported in cost of product revenues, but excluding any possible future amortization associated with acquired in-process research and development) is expected to approximate $31.9 million in 2015, $29.7 million in 2016, $27.6 million in 2017, $27.3 million in 2018 and $26.5 million in 2019. Identifiable intangible assets are initially recorded at fair market value at the time of acquisition using an income or cost approach.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References+ Details

DEBT

6 Months Ended

Jun. 30, 2015

Debt Disclosure [Abstract]

DEBT

Amended and Restated Senior Credit Agreement

On December 19, 2014, the Company entered into an amendment to the amended and restated credit agreement (the "Senior Credit Facility") which modified covenants to permit the distribution and/or dividend by the Company of its spine business to the Company's public stockholders. The intent of the amendment was to permit the Company to consummate the spine business spin-off transaction.

On July 2, 2014, the Company entered into the Senior Credit Facility with a syndicate of lending banks, Bank of America, N.A., as Administrative Agent, Swing Line Lender and L/C Issuer, Wells Fargo Bank, National Association, as Syndication Agent and HSBC Bank USA, National Association, Royal Bank of Canada, Citizens Bank, National Association, DNB Capital LLC, Credit Agricole-Corporate and Investment Bank and TD Bank, N.A., as Co-Documentation Agents. The Company's Senior Credit Facility was originally amended and restated on August 10, 2010, and that agreement was then amended on June 8, 2011, May 11, 2012, and June 21, 2013, as previously disclosed.

The 2014 amended and restated Senior Credit Facility created an aggregate principal amount of up to $900.0 million available to the Company through the following facilities:


i.	a $750.0 million revolving credit facility (increased from $600.0 million), which includes a $60.0 million sublimit for the issuance of standby letters of credit and a $60.0 million sublimit for swingline loans, and


ii.	a $150.0 million term loan facility.

The Senior Credit Facility allows the Company to further increase the size of either the revolving credit facility or the term loan facility, or a combination thereof, by an aggregate of $200.0 million with additional commitments. The July 2014 amended and restated Senior Credit Facility extended the maturity date of the prior facility from June 8, 2016 to July 2, 2019.

Borrowings under the Senior Credit Facility bear interest, at the Company’s option, at a rate equal to:


i.	the Eurodollar Rate (as defined in the amendment and restatement) in effect from time to time plus the applicable rate (ranging from 1.00% to 1.75%), or


ii.	the highest of:


1.	the weighted average overnight Federal funds rate, as published by the Federal Reserve Bank of New York, plus 0.50%, or


2.	the prime lending rate of Bank of America, N.A., or


3.	the one-month Eurodollar Rate plus 1.00%.

The applicable rates are based on the Company’s consolidated total leverage ratio (defined as the ratio of (a) consolidated funded indebtedness less cash in excess of $40.0 million that is not subject to any restriction of the use or investment thereof to (b) consolidated EBITDA) at the time of the applicable borrowing.

The Company will also pay an annual commitment fee (ranging from 0.15% to 0.30%, based on the Company’s consolidated total leverage ratio) on the daily amount by which the revolving credit facility exceeds the outstanding loans and letters of credit under the credit facility.

The Senior Credit Facility is collateralized by substantially all of the assets of the Company’s U.S. subsidiaries, excluding intangible assets. The Senior Credit Facility is subject to various financial and negative covenants and at June 30, 2015 the Company was in compliance with all such covenants. In connection with the modification of the 2014 amendment and restatement of the Senior Credit Facility, the Company capitalized $3.2 million of incremental financing costs, and expensed $0.3 million of previously capitalized financing costs.

On July 2, 2014, the Company borrowed $422.0 million under the Senior Credit Facility consisting of a $150.0 million term loan and $272.0 million under its revolving credit facility. The Company used the funds to repay the balance of its previous Senior Credit Facility. The outstanding borrowings have one, two, three, six months, or, if available, twelve months interest periods.

At June 30, 2015 and December 31, 2014, there was $286.9 million and $266.9 million outstanding under the revolving credit component of the Senior Credit Facility at a weighted average interest rate of 2.0% and 1.7%, respectively. At June 30, 2015, there was approximately $463.1 million available for borrowing under the Senior Credit Facility. The Company considers the balance to be long-term in nature based on its current intent and ability to repay the borrowing outside of the next twelve-month period.

At June 30, 2015 there was $150.0 million outstanding under the term loan component of the Senior Credit Facility at a weighted average interest rate of 1.8%. Contractual repayments of the term loan do not begin until September 30, 2015 and are due as follows:



Year Ended December 31,	Principal Repayment
	(In thousands)
2015	$	3,750
2016	9,375
2017	13,125
2018	15,000
2019	108,750
	$	150,000

The fair value of outstanding borrowings of the Senior Credit Facility's revolving credit facility and term loan components at June 30, 2015 was approximately $269.1 million and $143.0 million, respectively. These fair values were determined by using a discounted cash flow model based on current market interest rates available to the Company. These inputs are corroborated by observable market data for similar liabilities and therefore classified within Level 2 of the fair value hierarchy. Level 2 inputs represent inputs that are observable for the asset or liability, either directly or indirectly and are other than active market observable inputs that reflect unadjusted quoted prices for identical assets or liabilities.

2016 Convertible Senior Notes

On June 15, 2011, the Company issued $230.0 million aggregate principal amount of its 1.625% Convertible Senior Notes due in 2016 (the “2016 Notes”). The 2016 Notes mature on December 15, 2016, and bear interest at a rate of 1.625% per annum payable semi-annually in arrears on December 15 and June 15 of each year. The portion of the debt proceeds that was classified as equity at the time of the offering was $43.2 million, an equivalent of that amount is being amortized to interest expense using the effective interest method through December 2016. The effective interest rate implicit in the liability component is 5.6%.

At June 30, 2015, the carrying amount of the liability component was $217.3 million, the remaining unamortized discount was $12.7 million, and the principal amount outstanding was $230.0 million. The fair value of the 2016 Notes at June 30, 2015 was approximately $285.8 million. At December 31, 2014, the carrying amount of the liability component was $213.1 million, the remaining unamortized discount was $16.9 million and the principal amount outstanding was $230.0 million. The fair value of the liability of the 2016 Notes was determined using a discounted cash flow model based on current market interest rates available to the Company. These inputs are corroborated by observable market data for similar liabilities and therefore classified within Level 2.

The 2016 Notes are senior, unsecured obligations of the Company, and are convertible into cash and, if applicable, shares of its common stock based on an initial conversion rate, subject to adjustment of 17.4092 shares per $1,000 principal amount of 2016 Notes (which represents an initial conversion price of approximately $57.44 per share). The Company will satisfy any conversion of the 2016 Notes with cash up to the principal amount of the 2016 Notes pursuant to the net share settlement mechanism set forth in the indenture and, with respect to any excess conversion value, with shares of the Company’s common stock. The 2016 Notes are convertible only in the following circumstances: (1) if the closing sale price of the Company’s common stock exceeds 150% of the conversion price during a period as defined in the indenture; (2) if the average trading price per $1,000 principal amount of the 2016 Notes is less than or equal to 98% of the average conversion value of the 2016 Notes during a period as defined in the indenture; (3) at any time on or after June 15, 2016; or (4) if specified corporate transactions occur. The issue price of the 2016 Notes was equal to their face amount, which is also the amount holders are entitled to receive at maturity if the 2016 Notes are not converted. As of March 31, 2015, certain conversion features were triggered due to the announced spin-off of the Company's subsidiary, SeaSpine Holdings Corporation, which allowed the holders to convert all or any of the 2016 Notes subject to certain conditions. The 2016 Notes were convertible through June 10, 2015 and as of the close of the conversion window, 2,903 note holders provided notice to convert. The Company has classified the cash settlement of the conversion into short-term as of June 30, 2015. The remainder of the debt has continued to be classified as long-term as the conversion window has closed.

In connection with the issuance of the 2016 Notes, the Company entered into call transactions and warrant transactions, primarily with affiliates of the initial purchasers of such notes (the “hedge participants”). The initial strike price of the call transaction is approximately $57.44 per share, subject to customary anti-dilution adjustments. The initial strike price of the warrant transaction is approximately $70.05 per share, subject to customary anti-dilution adjustments. Refer to Note 14 - Subsequent Events for more information on the change in the conversion price as a result of the SeaSpine Separation.

Convertible Note Interest

The interest expense components of the Company’s convertible notes are as follows (net of capitalized interest amounts):



	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2014		2015		2014
	(In thousands)
2016 Notes:
Amortization of the discount on the liability component	$	1,885	$	1,766	$	3,744	$	3,433
Cash interest related to the contractual interest coupon	824		837		1,669		1,639
Total	$	2,709	$	2,603	$	5,413	$	5,072

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References+ Details

DERIVATIVE INSTRUMENTS

6 Months Ended

Jun. 30, 2015

Derivative Instruments and Hedging Activities Disclosure [Abstract]

DERIVATIVE INSTRUMENTS

Interest Rate Hedging

The Company’s interest rate risk relates to U.S. dollar denominated variable LIBOR interest rate borrowings. The Company uses an interest rate swap derivative instrument entered into on August 10, 2010 with an effective date of December 31, 2010 to manage its earnings and cash flow exposure to changes in interest rates by converting a portion of its floating-rate debt into fixed-rate debt beginning on December 31, 2010. This interest rate swap expires on August 10, 2015.

The Company designates this derivative instrument as a cash flow hedge. The Company records the effective portion of any change in the fair value of a derivative instrument designated as a cash flow hedge as unrealized gains or losses in accumulated other comprehensive income (“AOCI”), net of tax, until the hedged item affects earnings, at which point the effective portion of any gain or loss will be reclassified to earnings. If the hedged cash flow does not occur, or if it becomes probable that it will not occur, the Company will reclassify the amount of any gain or loss on the related cash flow hedge to interest expense at that time.

The Company expects that approximately $0.2 million of pre-tax losses recorded as net in AOCI related to the interest rate hedge could be reclassified to earnings prior to the date of expiration.

Foreign Currency Hedging

From time to time the Company enters into foreign currency hedge contracts intended to protect the U.S. dollar value of certain forecasted foreign currency denominated transactions. The Company records the effective portion of any change in the fair value of foreign currency cash flow hedges in AOCI, net of tax, until the hedged item affects earnings. Once the related hedged item affects earnings, the Company reclassifies the effective portion of any related unrealized gain or loss on the foreign currency cash flow hedge to earnings. If the hedged forecasted transaction does not occur, or if it becomes probable that it will not occur, the Company will reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time.

The success of the Company’s hedging program depends, in part, on forecasts of certain activity denominated in euros. The Company may experience unanticipated currency exchange gains or losses to the extent that there are differences between forecasted and actual activity during periods of currency volatility. In addition, changes in currency exchange rates related to any unhedged transactions may affect its earnings and cash flows.

There were no contracts outstanding as of June 30, 2015.

Counterparty Credit Risk

The Company manages its concentration of counterparty credit risk on its derivative instruments by limiting acceptable counterparties to a group of major financial institutions with investment grade credit ratings, and by actively monitoring their credit ratings and outstanding positions on an ongoing basis. Therefore, the Company considers the credit risk of the counterparties to be low. Furthermore, none of the Company’s derivative transactions are subject to collateral or other security arrangements, and none contain provisions that depend upon the Company’s credit ratings from any credit rating agency.

Fair Value of Derivative Instruments

The Company has classified all of its derivative instruments within Level 2 of the fair value hierarchy because observable inputs are available for substantially the full term of the derivative instruments. The fair value of the foreign currency forward exchange contracts related to inventory purchases is determined by comparing the forward rate as of the period end and the settlement rate specified in each contract. The fair value of the interest rate swaps was developed using a market approach based on publicly available market yield curves and the terms of the related swap. The Company performs ongoing assessments of counterparty credit risk.

The following table summarizes the fair value and presentation for derivatives designated as hedging instruments in the condensed consolidated balance sheets as of June 30, 2015 and December 31, 2014:



	Fair Value as of
Location on Balance Sheet ⁽¹⁾:	June 30, 2015		December 31, 2014
	(In thousands)
Derivatives designated as hedges — Liabilities:
Interest rate swap — Accrued expenses and other current liabilities ⁽²⁾	$	161	$	898
Total Derivatives designated as hedges — Liabilities	$	161	$	898


⁽¹⁾	The Company classifies derivative assets and liabilities as current based on the cash flows expected to be incurred within the following 12 months.


⁽²⁾	At June 30, 2015 and December 31, 2014, the notional amount related to the Company’s sole interest rate swap was $90.0 million and $97.5 million, respectively. In the next twelve months, the Company expects to reduce the notional amount by the entire $90.0 million.

The following presents the effect of derivative instruments designated as cash flow hedges on the accompanying condensed consolidated statements of operations during the three and six months ended June 30, 2015 and 2014:



	Balance in AOCI Beginning of Quarter			Amount of Loss Recognized in AOCI- Effective Portion			Amount of Loss Reclassified from AOCI into Earnings-Effective Portion			Balance in AOCI End of Quarter			Location in Statements of Operations
	(In thousands)
Three Months Ended June 30, 2015
Interest rate swap	(527		)	(7		)	(373		)	(161		)	Interest (expense)
	$	(527	)	$	(7	)	$	(373	)	$	(161	)
Three Months Ended June 30, 2014
Interest rate swap	(2,097		)	(60		)	(444		)	(1,713		)	Interest (expense)
	$	(2,097	)	$	(60	)	$	(444	)	$	(1,713	)

	Balance in AOCI Beginning of Quarter			Amount of Loss Recognized in AOCI- Effective Portion			Amount of Loss Reclassified from AOCI into Earnings-Effective Portion			Balance in AOCI End of Quarter			Location in Statements of Operations
	(In thousands)
Six Months Ended June 30, 2015
Interest rate swap	(898		)	(25		)	(762		)	(161		)	Interest (expense)
	$	(898	)	$	(25	)	$	(762	)	$	(161	)

Six Months Ended June 30, 2014
Interest rate swap	(2,439		)	(169		)	(895		)	(1,713		)	Interest (expense)
	$	(2,439	)	$	(169	)	$	(895	)	$	(1,713	)

The Company recognized no gains or losses resulting from ineffectiveness of cash flow hedges during the six months ended June 30, 2015 and 2014.

- Definition

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4K

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5708775-113959

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4B

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624163-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4J

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5708773-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 25

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4A

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5618551-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4H

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624258-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4E

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624181-113959

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80748-113994

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(n))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80784-113994

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4D

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624177-113959

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=35706170&loc=d3e41620-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5579245-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 1B

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5580258-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5579240-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=35706170&loc=d3e41641-113959

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=35706170&loc=d3e41638-113959

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4C

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624171-113959

+ Details

STOCK-BASED COMPENSATION	6 Months Ended
STOCK-BASED COMPENSATION	Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION As of June 30, 2015, the Company had stock options, restricted stock awards, performance stock units, contract stock awards and restricted stock unit awards outstanding under three plans, the 2000 Equity Incentive Plan (the “2000 Plan”), the 2001 Equity Incentive Plan (the “2001 Plan”), and the 2003 Equity Incentive Plan (the “2003 Plan,” and collectively, the “Plans”). Stock options issued under the Plans become exercisable over specified periods, generally within four years from the date of grant for officers, directors, and employees, and generally expire eight years from the grant date for employees, and from eight to ten years for directors and certain executive officers. Restricted stock issued under the Plans vests over specified periods, generally three years after the date of grant. The vesting of performance stock, issued under the Plans, is subject to service and performance conditions. Stock Options As of June 30, 2015, there were approximately $2.4 million of total unrecognized compensation costs related to unvested stock options. These costs are expected to be recognized over a weighted-average period of approximately two years. There were 77,347 stock options granted during the six months ended June 30, 2015. Awards of Restricted Stock, Performance Stock and Contract Stock Performance stock, restricted stock and contract stock awards generally have requisite service periods of three years. Performance stock units are subject to graded vesting conditions and the Company expenses their fair value over the requisite service period. The Company expenses the fair value of restricted stock and contract stock awards on a straight-line basis over the vesting period or requisite service period, whichever is shorter. As of June 30, 2015, there were approximately $18.4 million of total unrecognized compensation costs related to these unvested awards. The Company expects to recognize these costs over a weighted-average period of approximately two years. The Company granted 146,300 restricted stock awards/stock units and 64,930 performance shares during the six months ended June 30, 2015. The Company has no formal policy related to the repurchase of shares for the purpose of satisfying stock-based compensation obligations. The Company also maintains an Employee Stock Purchase Plan (the “ESPP”), which provides eligible employees with the opportunity to acquire shares of common stock at periodic intervals by means of accumulated payroll deductions. The ESPP is a non-compensatory plan based on its terms.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References+ Details

INCOME TAXES

6 Months Ended

Jun. 30, 2015

Income Tax Disclosure [Abstract]

INCOME TAXES

The following table provides a summary of the Company’s effective tax rate:



	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2014		2015		2014

Reported tax rate	34.0	%	32.9	%	33.7	%	37.0	%

The Company’s effective income tax rates for the three months ended June 30, 2015 and 2014 were 34.0% and 32.9%, respectively. The primary drivers of the higher tax rate for the three months ended June 30, 2015 were a tax expense of $0.4 million for nondeductible costs relating to the spine spin-off transaction and a tax expense of $0.4 million relating to foreign tax returns filed during the quarter.

The Company's effective income tax rates for the six months ended June 30, 2015 and 2014 were 33.7% and 37.0%, respectively. The primary drivers of the overall tax rate for the six months ended June 30, 2014 were a tax expense of $1.1 million relating to foreign and state income tax audit settlements and a tax expense of $0.3 million relating to a change in state filing positions.

The Company expects its effective income tax rate for the full year to be approximately 32%, resulting largely from nondeductible spine spin-off costs and audit settlements offset by the release of uncertain tax positions, as well as the jurisdictional mix of pretax income in U.S.-based operations relative to foreign operations. This estimate could be revised in the future as additional information is presented to the Company.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References+ Details

NET INCOME PER SHARE

6 Months Ended

Jun. 30, 2015

Earnings Per Share [Abstract]

NET INCOME PER SHARE

Basic and diluted net income per share was as follows:



	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2014		2015		2014
	(In thousands, except per share amounts)
Basic net income per share:
Net income	$	4,998	$	4,825	$	13,382	$	7,031
Weighted average common shares outstanding	33,032		32,398		32,884		32,336
Basic net income per common share	$	0.15	$	0.15	$	0.41	$	0.22

Diluted net income per share:
Net income	$	4,998	$	4,825	$	13,382	$	7,031

Weighted average common shares outstanding — Basic	33,032		32,398		32,884		32,336
Effect of dilutive securities:
2016 Convertible notes	477		—		268		—
Stock options and restricted stock	430		406		492		460
Weighted average common shares for diluted earnings per share	33,939		32,804		33,644		32,796
Diluted net income per common share	$	0.15	$	0.15	$	0.40	$	0.21

At June 30, 2015 and 2014, the Company had 1.1 million and 1.4 million of outstanding stock options, respectively. The Company also has warrants outstanding relating to its 2016 Notes at June 30, 2015 and 2014 and the Company's 2016 Notes are convertible to common shares in certain circumstances (see Note 5). Stock options, restricted stock, warrants and the excess conversion value of the 2016 Notes are included in the diluted earnings per share calculation using the treasury stock method, unless the effect of including such items would be anti-dilutive.

For the three months ended June 30, 2015 and 2014, 0.1 million and 0.2 million, respectively, of anti-dilutive stock options were excluded from the diluted earnings per share calculation. For the six months ended June 30, 2015 and 2014, a minimal amount and 0.2 million, respectively, of anti-dilutive stock options were excluded from the diluted earnings per share calculation. The effect of outstanding warrants were anti-dilutive because the strike price of the warrants exceeded the Company’s average stock price for the periods presented.

For the three and six months ended June 30, 2015, the potential excess conversion value on the 2016 Notes was included in the Company's dilutive share calculation because the average stock price for the three and six months ended June 30, 2015 exceeded the conversion price. The potential excess conversion value of the 2016 Notes were anti-dilutive because the conversion price exceeded the Company's stock price for the three and six months ended June 30, 2014; therefore, these amounts have been excluded from the diluted earnings per share calculation.

- Definition

The entire disclosure for earnings per share.

+ References+ Details

COMPREHENSIVE INCOME (LOSS)

6 Months Ended

Jun. 30, 2015

Equity [Abstract]

COMPREHENSIVE INCOME (LOSS)

Comprehensive income (loss) was as follows:



	Three Months Ended June 30,						Six Months Ended June 30,
	2015			2014			2015			2014
	(In thousands)
Net income	$	4,998		$	4,825		$	13,382		$	7,031
Foreign currency translation adjustment	7,166			(234		)	(17,227		)	585
Change in unrealized gain on derivatives, net of tax	209			219			420			414
Pension liability adjustment, net of tax	(48		)	(58		)	7			(73		)
Comprehensive income (loss)	$	12,325		$	4,752		$	(3,418	)	$	7,957

Changes in Accumulated Other Comprehensive Loss by component between December 31, 2014 and June 30, 2015 are presented in the table below, net of tax:



	Gains and (Losses) on Cash Flow Hedges			Defined Benefit Pension Items			Foreign Currency Items			Total
	(In thousands)
Beginning balance	$	(512	)	$	(906	)	$	(22,070	)	$	(23,488	)
Other comprehensive (loss) income before reclassifications	(14		)	7			(17,227		)	(17,234		)
Amounts reclassified from accumulated other comprehensive income	434			—			—			434
Net current-period other comprehensive income (loss)	420			7			(17,227		)	(16,800		)
Ending balance	$	(92	)	$	(899	)	$	(39,297	)	$	(40,288	)

The reclassification adjustments out of Accumulated Other Comprehensive Loss during the three and six months ended June 30, 2015 were as follows:



Three Months Ended June 30, 2015
Details about Accumulated Other Comprehensive Income (Loss) Components	Amount Reclassified from Accumulated Other Comprehensive Income (Loss)			Affected Line Item in the Statement where Net Income (Loss) is Presented
	(In thousands)
Gains and losses on cash flow hedges
Interest rate swap	$	(373	)	Interest (expense)
	160			Tax (expense) or benefit
	$	(213	)	Net of tax

Six Months Ended June 30, 2015
Details about Accumulated Other Comprehensive Income (Loss) Components	Amount Reclassified from Accumulated Other Comprehensive Income (Loss)			Affected Line Item in the Statement where Net Income (Loss) is Presented
	(In thousands)
Gains and losses on cash flow hedges
Interest rate swap	$	(761	)	Interest (expense)
	327			Tax (expense) or benefit
	$	(434	)	Net of tax

- Definition

The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e689-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669619-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e640-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 17

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e716-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e709-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Reclassification Adjustments

-URI http://asc.fasb.org/extlink&oid=6522872

+ Details

SEGMENT AND GEOGRAPHIC INFORMATION

6 Months Ended

Jun. 30, 2015

Segment Reporting [Abstract]

SEGMENT AND GEOGRAPHIC INFORMATION

Starting in the first quarter of 2015, because of changes in how the Company internally manages and reports the results of its businesses to its chief operating decision maker, the Company is disclosing three global reportable segments. The three global reportable segments and their activities are described below, as follows:

•

The Specialty Surgical Solutions segment includes (i) the Neurosurgery business which sells a full line of products specifically for neurosurgery and critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment and (ii) the Instruments business which sells more than 60,000 instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices.


•	The Orthopedics and Tissue Technologies segment includes such offerings as skin and wound repair, bone and joint fixation, implants in the upper and lower extremities, bone grafts and nerve and tendon repair.

•

The Spine segment focuses on spinal fusion, spinal implants, and deformity correction, together with bone graft substitutes and other related medical devices that are used to enhance the repair and regeneration of bone in various types of orthopedic surgical procedures. Subsequent to June 30, 2015, this operating segment was eliminated due to the spin-off of the SeaSpine business. Refer to Note 14 - Subsequent Events for additional information.

The most notable change from the Company's financial statements for the year ended December 31, 2014 included in the Annual Report on Form 10-K is the integration of the former International reportable segment into the segments noted above as well as the Private Label segment into Orthopedics and Tissue Technologies and Spine.

The Corporate and other category includes (i) various legal, finance, information systems, executive, and human resource functions, (ii) brand management, and (iii) share-based compensation costs. Prior to the realignment, costs related to procurement, manufacturing operations and logistics for the Company's entire organization were not allocated to operating segments. In connection with the realignment, a portion of these costs have now been incorporated into the disclosed operating segments.

The operating results of the various reportable segments as presented are not comparable to one another because (i) certain operating segments are more dependent than others on corporate functions for unallocated general and administrative and/or operational manufacturing functions, and (ii) the Company does not allocate certain manufacturing costs and general and administrative costs to the operating segment results. Net sales and profit by reportable segment for the three and six months ended June 30, 2015 and 2014 are as follows:



	Three Months Ended June 30,						Six Months Ended June 30,
	2015			2014			2015		2014
	(In thousands)
Segment Net Sales
Specialty Surgical Solutions	$	146,709		$	137,516		$	286,769	$	264,710
Orthopedics and Tissue Technologies	63,834			57,954			125,199		112,544
Spine	33,535			35,881			65,775		69,156
Total revenues	$	244,078		$	231,351		$	477,743	$	446,410
Segment Profit
Specialty Surgical Solutions	$	62,325		$	48,991		$	122,657	$	97,288
Orthopedics and Tissue Technologies	18,428			20,019			38,010		37,020
Spine	1,266			4,101			1,578		6,849
Segment profit	82,019			73,111			162,245		141,157
Amortization	(3,104		)	(2,985)			(6,639)		(6,018)
Corporate and other	(64,961		)	(57,734		)	(124,864)		(114,009		)
Operating income	$	13,954		$	12,392		$	30,742	$	21,130

The Company attributes revenues to geographic areas based on the location of the customer. There are certain revenues managed by the various U.S. segments that are generated from non-U.S. customers and therefore are included in Europe and the Rest of World revenues below. Total revenue by major geographic area consisted of the following:



	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2014		2015		2014
	(In thousands)
United States	$	190,093	$	178,806	$	371,030	$	342,187
Europe	27,497		25,851		54,258		51,176
Rest of World	26,488		26,694		52,455		53,047
Total Revenues	$	244,078	$	231,351	$	477,743	$	446,410

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 32

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 29

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 34

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 35

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 41

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 42

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 31

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 40

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 33

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

+ Details

COMMITMENTS AND CONTINGENCIES	6 Months Ended
COMMITMENTS AND CONTINGENCIES	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES In consideration for certain technology, manufacturing, distribution, and selling rights and licenses granted to the Company, the Company has agreed to pay royalties on sales of certain products that it sells. The royalty payments that the Company made under these agreements were not significant for any of the periods presented. The Company is subject to various claims, lawsuits and proceedings in the ordinary course of the Company's business, including claims by current or former employees, distributors and competitors and with respect to its products and product liability claims, lawsuits and proceedings, some of which have been settled by the Company. In the opinion of management, such claims are either adequately covered by insurance or otherwise indemnified, or are not expected, individually or in the aggregate, to result in a material adverse effect on our financial condition. However, it is possible that the Company's results of operations, financial position and cash flows in a particular period could be materially affected by these contingencies. The Company accrues for loss contingencies when it is deemed probable that a loss has been incurred and that loss is estimable. The amounts accrued are based on the full amount of the estimated loss before considering insurance proceeds, and do not include an estimate for legal fees expected to be incurred in connection with the loss contingency. The Company consistently accrues legal fees expected to be incurred in connection with loss contingencies as those fees are incurred by outside counsel as a period cost.

- Definition

The entire disclosure for commitments and contingencies.

+ References+ Details

SUBSEQUENT EVENTS	6 Months Ended
SUBSEQUENT EVENTS	Jun. 30, 2015
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS SeaSpine Separation On November 1, 2014, the Company announced plans to spin-off the spine business into a stand-alone public company ("SeaSpine"). On July 1, 2015, the Company completed the distribution of 100% of the outstanding common shares of SeaSpine to Integra stockholders who received one share of SeaSpine common stock for every three shares of Integra held as of the close of business on the record date, June 19, 2015. The historical results of operations and the financial position of SeaSpine are included in the consolidated financial statements of Integra and will be reported as discontinued operations beginning in the third quarter of 2015. As a result of the spin-off and pursuant to the indenture for the Company's 2016 Notes, the conversion price and rate is required to be adjusted. The conversion price on the 2016 Notes has been adjusted to $52.83 per share and the new conversion rate is 18.9287 shares per $1,000 principal amount of 2016 Notes. Similarly, the strike price of the call transaction has been adjusted to $52.83 per share and the warrant transaction has been adjusted to $64.43 per share. Acquisition of TEI Biosciences, Inc. and TEI Medical, Inc. On July 17, 2015, the Company completed the execution of the two merger agreements (collectively, the "Agreements") under which the Company acquired TEI Biosciences, Inc., a Delaware corporation ("TEI Bio"), and TEI Medical Inc., a Delaware corporation ("TEI Med", collectively "TEI"). TEI Bio is in the business of developing and commercializing biologic devices for soft tissue repair and regenerative applications, including dura and hernia repair and plastic and reconstructive surgery. TEI Med is a spin-off of TEI Bio and holds a license to TEI Bio’s regenerative technology in the fields of wound healing and orthopedics. Under the terms of the Agreements, the Company paid $312.0 million ($211.0 million for TEI Bio and $101.0 million for TEI Med) subject in each case to purchase price adjustments for certain working capital changes. In July 2015, the Company drew $310.0 million on its Revolving Credit Facility to facilitate this transaction. The Company has not yet performed the purchase price allocation and will do so in the third quarter of 2015. TEI manufactures a bovine-derived surgical mesh product for Boston Scientific Corporation ("BSC”) and has been named as a defendant in several hundred lawsuits under a broad range of products liability theories, many of which have not been served on TEI. Currently, there are approximately forty-five active cases against TEI. Pursuant to an indemnification agreement with BSC (i) BSC is managing the litigation; (ii) TEI has in place a products liability insurance policy, of which it must exhaust $3.0 million before BSC’s indemnity begins to cover relevant claims (and of which only a small portion has been utilized to date and against which the insurer has reserved the entire $3.0 million). Because the thrust of products liability litigation focuses on synthetic surgical mesh products, counsel is filing motions to dismiss on behalf of TEI in many cases. In addition, Integra has certain protections in the merger agreements with TEI which would indemnify it for approximately $30.0 million for the first fifteen months after closing and between $20.0 and $30.0 million for the remainder of the three-year period after closing for losses relating to a variety of matters, including half of certain products liability claims (including those related to the product it manufactures for BSC) not covered by insurance.

BASIS OF PRESENTATION (Policies)	6 Months Ended
BASIS OF PRESENTATION (Policies)	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Recently Issued Accounting Standards	Recently Issued Accounting Standards In April 2014, the FASB issued amendments to guidance for reporting discontinued operations and disposals of components of an entity. The amended guidance requires that a disposal representing a strategic shift that has (or will have) a major effect on an entity’s financial results or a business activity classified as held for sale should be reported as discontinued operations. The amendments also expand the disclosure requirements for discontinued operations and add new disclosures for individually significant dispositions that do not qualify as discontinued operations. The amendments are effective prospectively for fiscal years, and interim reporting periods within those years, beginning after December 15, 2014 (early adoption is permitted only for disposals that have not been previously reported). The new guidance is effective for Integra prospectively for all disposals (or classifications as held for sale) of components of an entity that occur after January 1, 2015 and will be in effect for the spin-off of the spine business in the Company's third quarter 2015 results. In May 2014, the FASB issued Update No. 2014-09, Revenue from Contracts with Customers (Topic 606). The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should 1) identify the contract(s) with a customer, 2) identify the performance obligations in the contract, 3) determine the transaction price, 4) allocate the transaction price to the performance obligations in the contract, and 5) recognize revenue when (or as) the entity satisfies a performance obligation. In July 2015, the FASB deferred for one year the effective date of the new revenue standard, but early adoption will be permitted. The new standard will be effective for the Company on January 1, 2018. The Company is in the process of evaluating the impact of this standard on its financial statements. In June 2014, the FASB issued Update No. 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period (Topic 718). The amendments require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Topic 718 as it relates to awards with performance conditions that affect vesting to account for such awards. As such, the performance target should not be reflected in estimating the grant-date fair value of the award. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. If the performance target becomes probable of being achieved before the end of the requisite service period, the remaining unrecognized compensation cost should be recognized prospectively over the remaining requisite service period. The requisite service period ends when the employee can cease rendering service and still be eligible to vest in the award if the performance target is achieved. This update is effective for annual reporting periods beginning after December 15, 2015, including interim periods within that reporting period, and early adoption is permitted. The implementation of the amended guidance is not expected to have a material impact on the consolidated financial position or results of operations. In August 2014, the FASB issued Update No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The amendment requires management to evaluate, for each annual and interim reporting period, whether there are conditions and events, considered in the aggregate, that raise substantial doubt about an entity’s ability to continue as a going concern within one year after the date the financial statements are issued or are available to be issued. If substantial doubt is raised, additional disclosures around management’s plan to alleviate these doubts are required. This update will become effective for all annual periods and interim reporting periods beginning after December 15, 2016. The implementation of the amended guidance is not expected to have an impact on current disclosures in the financial statements. In April 2015, the FASB issued Update No. 2015-03, Simplifying the Presentation of Debt Issuance Costs. The amendment requires that all costs incurred to issue debt be presented in the balance sheet as a direct deduction from the carrying value of the debt. The new standard is limited to the presentation of debt issuance costs and does not affect the recognition or measurement of debt issuance costs. This update will become effective for all annual periods and interim reporting periods beginning after December 15, 2015. The implementation of the amended guidance is not expected to have a material impact on the consolidated results of operations and will result in a reclassification of the debt issuance costs from other long-term assets to long-term debt when adopted. There are no other recently issued accounting pronouncements that are expected to have a material effect on the financial position, results of operations or cash flows.

BUSINESS ACQUISITIONS (Tables)

6 Months Ended

Jun. 30, 2015

Business Combinations [Abstract]

Schedule of Purchase Price Allocation

The following summarizes the preliminary allocation of the purchase price as of June 30, 2015 based on the fair value of the assets acquired and liabilities assumed:



	Preliminary Purchase Price Allocation
	(Dollars in thousands)
Inventory	$	4,800
Property, plant, and equipment	1,246
Intangible assets:			Wtd. Avg. Life:
Technology product rights	20,590		8 - 14 Years
In-process research and development	190		Indefinite
Goodwill	732
Net assets acquired	$	27,558

The following summarizes the final allocation of the purchase price as of June 30, 2015 based on the fair value of the assets acquired and liabilities assumed:



	Final Purchase Price Allocation
	(Dollars in thousands)
Inventory deposit	$	4,000
Fixed assets	438
Intangible assets:			Wtd. Avg. Life
Technology product rights	239,800		3 - 20 Years
Other	400		Less than 1 year
Deferred tax assets - long term	12
Goodwill	105,331
Total assets acquired	349,981
Contingent supply liability	5,891
Other	731
Deferred tax liabilities - long term	87,464
Net assets acquired	$	255,895

The following summarizes the final allocation of the purchase price as of June 30, 2015 based on the fair value of the assets acquired and liabilities assumed:



	Final Purchase Price Allocation
	(Dollars in thousands)
Cash	$	2,195
Inventory	3,155
Prepaid expenses	620
Property, plant, and equipment	3,675
Other current assets	5,025
Intangible assets:			Wtd. Avg. Life:
Trade name	11,990		20 Years
Technology	4,580		15 - 16 Years
Customer relationships	18,130		12 - 16 Years
Goodwill	16,607
Total assets acquired	65,977
Accounts payable and other liabilities	5,910
Net assets acquired	$	60,067

Schedule of Contingent Consideration

A reconciliation of the opening balances to the closing balances of these Level 3 measurements is as follows (in thousands):



			Location in Statement of Operations
Balance as of January 1, 2015	$	22,008
Loss from increase in fair value of contingent consideration liabilities	239		Selling, general and administrative
Fair value at June 30, 2015	$	22,247

Pro Forma Information

As a result, these pro forma results do not necessarily represent results that would have occurred if the acquisition had taken place on the basis assumed above, nor are they indicative of the results of future combined operations.



	Three Months Ended June 30, 2014		Six Months Ended June 30, 2014
	(In thousands, except per share amounts)
Total revenue	$	241,801	$	467,310
Net income	$	7,009	$	12,581
Net income per share:
Basic	$	0.22	$	0.39

- Definition

Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.

+ References+ Details

INVENTORIES (Tables)

6 Months Ended

Jun. 30, 2015

Inventory, Net [Abstract]

Schedule of Inventory, Net

Inventories, net consisted of the following:



	June 30, 2015		December 31, 2014
	(In thousands)
Finished goods	$	146,912	$	150,483
Work in process	54,707		50,166
Raw materials	40,216		36,465
	$	241,835	$	237,114

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)

6 Months Ended

Jun. 30, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Changes In Carrying Amount Of Goodwill

Changes in the carrying amount of goodwill for the six months ended June 30, 2015 were as follows:



	Specialty Surgical Solutions			Orthopedics and Tissue Technologies			Spine			Total
	(In thousands)
Goodwill, gross	$	281,829		$	81,650		$	409		$	363,888
Accumulated impairment losses	—			—			—			—
Goodwill at December 31, 2014	281,829			81,650			409			363,888
MicroFrance working capital and purchase price adjustments	(828		)	—			—			(828		)
Metasurg working capital and purchase price adjustment	—			263			—			263
Goodwill impairment charge	—			—			(409		)	(409		)
Foreign currency translation	(4,451		)	(1,441		)	—			(5,892		)
Balance, June 30, 2015	$	276,550		$	80,472		$	—		$	357,022

Components of Company's Identifiable Intangible Assets

The components of the Company’s identifiable intangible assets were as follows:



	June 30, 2015
	Weighted Average Life	Cost		Accumulated Amortization			Net
	(Dollars in thousands)
Completed technology	18 years	$	344,406	$	(72,393	)	$	272,013
Customer relationships	12 years	159,548		(91,621		)	67,927
Trademarks/brand names	34 years	43,221		(15,814		)	27,407
Trademarks/brand names	Indefinite	48,484		—			48,484
Supplier relationships	27 years	34,721		(11,522		)	23,199
All other⁽¹⁾	4 years	2,721		(1,168		)	1,553
		$	633,101	$	(192,518	)	$	440,583



	December 31, 2014
	Weighted Average Life	Cost		Accumulated Amortization			Net
	(Dollars in thousands)
Completed technology	18 years	$	345,082	$	(62,920	)	$	282,162
Customer relationships	12 years	162,031		(87,653		)	74,378
Trademarks/brand names	34 years	44,520		(15,755		)	28,765
Trademarks/brand names	Indefinite	48,484		—			48,484
Supplier relationships	27 years	34,721		(10,809		)	23,912
All other⁽¹⁾	4 years	4,810		(3,052		)	1,758
		$	639,648	$	(180,189	)	$	459,459


⁽¹⁾	At June 30, 2015 and December 31, 2014, all other included in-process research and development ("IPR&D") of $1.4 million in both periods, which was indefinite-lived.

DEBT (Tables)

6 Months Ended

Jun. 30, 2015

Debt Disclosure [Abstract]

Schedule of Maturities of Long-term Debt



Year Ended December 31,	Principal Repayment
	(In thousands)
2015	$	3,750
2016	9,375
2017	13,125
2018	15,000
2019	108,750
	$	150,000

Components of Interest Expense

The interest expense components of the Company’s convertible notes are as follows (net of capitalized interest amounts):



	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2014		2015		2014
	(In thousands)
2016 Notes:
Amortization of the discount on the liability component	$	1,885	$	1,766	$	3,744	$	3,433
Cash interest related to the contractual interest coupon	824		837		1,669		1,639
Total	$	2,709	$	2,603	$	5,413	$	5,072

DERIVATIVE INSTRUMENTS (Tables)

6 Months Ended

Jun. 30, 2015

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Summary of Fair Value In Balance Sheet For Derivatives Designated As Hedging Instruments



	Fair Value as of
Location on Balance Sheet ⁽¹⁾:	June 30, 2015		December 31, 2014
	(In thousands)
Derivatives designated as hedges — Liabilities:
Interest rate swap — Accrued expenses and other current liabilities ⁽²⁾	$	161	$	898
Total Derivatives designated as hedges — Liabilities	$	161	$	898


⁽¹⁾	The Company classifies derivative assets and liabilities as current based on the cash flows expected to be incurred within the following 12 months.


⁽²⁾	At June 30, 2015 and December 31, 2014, the notional amount related to the Company’s sole interest rate swap was $90.0 million and $97.5 million, respectively. In the next twelve months, the Company expects to reduce the notional amount by the entire $90.0 million

Effect of Derivative Instruments Designated as Cash Flow Hedges on Statements of Operations



	Balance in AOCI Beginning of Quarter			Amount of Loss Recognized in AOCI- Effective Portion			Amount of Loss Reclassified from AOCI into Earnings-Effective Portion			Balance in AOCI End of Quarter			Location in Statements of Operations
	(In thousands)
Three Months Ended June 30, 2015
Interest rate swap	(527		)	(7		)	(373		)	(161		)	Interest (expense)
	$	(527	)	$	(7	)	$	(373	)	$	(161	)
Three Months Ended June 30, 2014
Interest rate swap	(2,097		)	(60		)	(444		)	(1,713		)	Interest (expense)
	$	(2,097	)	$	(60	)	$	(444	)	$	(1,713	)

	Balance in AOCI Beginning of Quarter			Amount of Loss Recognized in AOCI- Effective Portion			Amount of Loss Reclassified from AOCI into Earnings-Effective Portion			Balance in AOCI End of Quarter			Location in Statements of Operations
	(In thousands)
Six Months Ended June 30, 2015
Interest rate swap	(898		)	(25		)	(762		)	(161		)	Interest (expense)
	$	(898	)	$	(25	)	$	(762	)	$	(161	)

Six Months Ended June 30, 2014
Interest rate swap	(2,439		)	(169		)	(895		)	(1,713		)	Interest (expense)
	$	(2,439	)	$	(169	)	$	(895	)	$	(1,713	)

INCOME TAXES (Tables)

6 Months Ended

Jun. 30, 2015

Income Tax Disclosure [Abstract]

Schedule of effective income tax rate reconciliation

The following table provides a summary of the Company’s effective tax rate:



	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2014		2015		2014

Reported tax rate	34.0	%	32.9	%	33.7	%	37.0	%

NET INCOME PER SHARE (Tables)

6 Months Ended

Jun. 30, 2015

Earnings Per Share [Abstract]

Basic and Diluted Net Income Per Share

Basic and diluted net income per share was as follows:



	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2014		2015		2014
	(In thousands, except per share amounts)
Basic net income per share:
Net income	$	4,998	$	4,825	$	13,382	$	7,031
Weighted average common shares outstanding	33,032		32,398		32,884		32,336
Basic net income per common share	$	0.15	$	0.15	$	0.41	$	0.22

Diluted net income per share:
Net income	$	4,998	$	4,825	$	13,382	$	7,031

Weighted average common shares outstanding — Basic	33,032		32,398		32,884		32,336
Effect of dilutive securities:
2016 Convertible notes	477		—		268		—
Stock options and restricted stock	430		406		492		460
Weighted average common shares for diluted earnings per share	33,939		32,804		33,644		32,796
Diluted net income per common share	$	0.15	$	0.15	$	0.40	$	0.21

COMPREHENSIVE INCOME (LOSS) (Tables)

6 Months Ended

Jun. 30, 2015

Equity [Abstract]

Schedule of Comprehensive (Loss) Income

Comprehensive income (loss) was as follows:



	Three Months Ended June 30,						Six Months Ended June 30,
	2015			2014			2015			2014
	(In thousands)
Net income	$	4,998		$	4,825		$	13,382		$	7,031
Foreign currency translation adjustment	7,166			(234		)	(17,227		)	585
Change in unrealized gain on derivatives, net of tax	209			219			420			414
Pension liability adjustment, net of tax	(48		)	(58		)	7			(73		)
Comprehensive income (loss)	$	12,325		$	4,752		$	(3,418	)	$	7,957

Schedule of Changes in Accumulated Other Comprehensive Income by Component

Changes in Accumulated Other Comprehensive Loss by component between December 31, 2014 and June 30, 2015 are presented in the table below, net of tax:



	Gains and (Losses) on Cash Flow Hedges			Defined Benefit Pension Items			Foreign Currency Items			Total
	(In thousands)
Beginning balance	$	(512	)	$	(906	)	$	(22,070	)	$	(23,488	)
Other comprehensive (loss) income before reclassifications	(14		)	7			(17,227		)	(17,234		)
Amounts reclassified from accumulated other comprehensive income	434			—			—			434
Net current-period other comprehensive income (loss)	420			7			(17,227		)	(16,800		)
Ending balance	$	(92	)	$	(899	)	$	(39,297	)	$	(40,288	)

Reclassification out of Accumulated Other Comprehensive Income (Loss)

The reclassification adjustments out of Accumulated Other Comprehensive Loss during the three and six months ended June 30, 2015 were as follows:



Three Months Ended June 30, 2015
Details about Accumulated Other Comprehensive Income (Loss) Components	Amount Reclassified from Accumulated Other Comprehensive Income (Loss)			Affected Line Item in the Statement where Net Income (Loss) is Presented
	(In thousands)
Gains and losses on cash flow hedges
Interest rate swap	$	(373	)	Interest (expense)
	160			Tax (expense) or benefit
	$	(213	)	Net of tax

Six Months Ended June 30, 2015
Details about Accumulated Other Comprehensive Income (Loss) Components	Amount Reclassified from Accumulated Other Comprehensive Income (Loss)			Affected Line Item in the Statement where Net Income (Loss) is Presented
	(In thousands)
Gains and losses on cash flow hedges
Interest rate swap	$	(761	)	Interest (expense)
	327			Tax (expense) or benefit
	$	(434	)	Net of tax

SEGMENT AND GEOGRAPHIC INFORMATION (Tables)

6 Months Ended

Jun. 30, 2015

Segment Reporting [Abstract]

Total Revenue By Major Geographic Area

Net sales and profit by reportable segment for the three and six months ended June 30, 2015 and 2014 are as follows:



	Three Months Ended June 30,						Six Months Ended June 30,
	2015			2014			2015		2014
	(In thousands)
Segment Net Sales
Specialty Surgical Solutions	$	146,709		$	137,516		$	286,769	$	264,710
Orthopedics and Tissue Technologies	63,834			57,954			125,199		112,544
Spine	33,535			35,881			65,775		69,156
Total revenues	$	244,078		$	231,351		$	477,743	$	446,410
Segment Profit
Specialty Surgical Solutions	$	62,325		$	48,991		$	122,657	$	97,288
Orthopedics and Tissue Technologies	18,428			20,019			38,010		37,020
Spine	1,266			4,101			1,578		6,849
Segment profit	82,019			73,111			162,245		141,157
Amortization	(3,104		)	(2,985)			(6,639)		(6,018)
Corporate and other	(64,961		)	(57,734		)	(124,864)		(114,009		)
Operating income	$	13,954		$	12,392		$	30,742	$	21,130



	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2014		2015		2014
	(In thousands)
United States	$	190,093	$	178,806	$	371,030	$	342,187
Europe	27,497		25,851		54,258		51,176
Rest of World	26,488		26,694		52,455		53,047
Total Revenues	$	244,078	$	231,351	$	477,743	$	446,410

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References+ Details

BUSINESS ACQUISITIONS - Narrative (Details) (USD $)	6 Months Ended		0 Months Ended	3 Months Ended	6 Months Ended	0 Months Ended	3 Months Ended	6 Months Ended	0 Months Ended	3 Months Ended		6 Months Ended				3 Months Ended
BUSINESS ACQUISITIONS - Narrative (Details) (USD $)	Jun. 30, 2015	Jun. 30, 2014	Dec. 05, 2014 Metasurg	Jun. 30, 2015 Metasurg	Jun. 30, 2015 Metasurg	Oct. 27, 2014 Medtronic MicroFrance	Jun. 30, 2015 Medtronic MicroFrance	Jun. 30, 2015 Medtronic MicroFrance	Jan. 15, 2014 Confluent Surgical, Inc.	Jun. 30, 2015 Confluent Surgical, Inc.	Jun. 30, 2014 Confluent Surgical, Inc.	Jun. 30, 2015 Confluent Surgical, Inc.	Jun. 30, 2014 Confluent Surgical, Inc.	Jan. 15, 2014 Confluent Surgical, Inc. Potential Cash Consideration Fair Value	Jan. 15, 2014 Confluent Surgical, Inc. Cash Consideration Two	Jun. 30, 2014 Deferred Tax Liability Confluent Surgical, Inc.
Business Acquisition [Line Items]
Consideration for acquisition			$ 27,600,000
Adjustment of consideration for acquisition			400,000		400,000	(1,500,000)		1,500,000
Payments for acquisition			26,500,000			60,100,000
Contingent consideration acquisition			700,000						20,900,000
Business acquisition, additional cash consideration payable upon completion of milestones			38,500,000						30,000,000					25,000,000	5,000,000
Fair value inputs, discount rate			19.90%						2.20%
Revenue of acquired company since acquisition				1,700,000	3,300,000		6,300,000	12,100,000		18,900,000	14,100,000	36,600,000	32,400,000
Adjustment to goodwill						800,000
Net assets acquired				27,558,000	27,558,000		60,067,000	60,067,000	255,895,000	255,895,000		255,895,000
Payments to acquire business interest									231,000,000
Payments for transitional supply agreements from acquisition									4,000,000
Contingent liability extension period									2 years
Consideration liability, number of required days for extension									180 days
Contingent liability, period of consideration arrangement									5 years
Contingent liability, period of transitional supply price increases									3 years
Working capital and purchase price adjustment																12,400,000
Impairment of intangible assets	409,000	600,000										600,000
Fair value input, probability of event									95.00%
Incremental increase in contingent liability									300,000
Incremental decrease in contingent liability									$ 400,000

BUSINESS ACQUISITIONS - Schedule of Purchase Price Allocation (Details) (USD $) In Thousands, unless otherwise specified						6 Months Ended				6 Months Ended		6 Months Ended			6 Months Ended				6 Months Ended
	Jun. 30, 2015	Dec. 31, 2014	Jun. 30, 2015 Metasurg	Jun. 30, 2015 Metasurg In Process Research and Development	Jun. 30, 2015 Metasurg Technology-Based Intangible Assets	Jun. 30, 2015 Metasurg Technology-Based Intangible Assets Minimum	Jun. 30, 2015 Metasurg Technology-Based Intangible Assets Maximum	Jun. 30, 2015 Medtronic MicroFrance	Jun. 30, 2015 Medtronic MicroFrance Trade Names	Jun. 30, 2015 Medtronic MicroFrance Trade Names Maximum	Jun. 30, 2015 Medtronic MicroFrance Technology-Based Intangible Assets	Jun. 30, 2015 Medtronic MicroFrance Technology-Based Intangible Assets Minimum	Jun. 30, 2015 Medtronic MicroFrance Technology-Based Intangible Assets Maximum	Jun. 30, 2015 Medtronic MicroFrance Customer relationships	Jun. 30, 2015 Medtronic MicroFrance Customer relationships Minimum	Jun. 30, 2015 Medtronic MicroFrance Customer relationships Maximum	Jun. 30, 2015 Confluent Surgical, Inc.	Jan. 15, 2014 Confluent Surgical, Inc.	Jun. 30, 2015 Confluent Surgical, Inc. Technology-Based Intangible Assets Minimum	Jun. 30, 2015 Confluent Surgical, Inc. Technology-Based Intangible Assets Maximum	Jun. 30, 2015 Confluent Surgical, Inc. Developed Technology Rights	Jun. 30, 2015 Confluent Surgical, Inc. Other Intangible Assets
Business Acquisition [Line Items]
Cash								$ 2,195
Inventory			4,800					3,155
Inventory deposit								620									4,000
Fixed assets			1,246					3,675									438
Other current assets								5,025
Finite intangible assets					20,590				11,990		4,580			18,130							239,800	400
Deferred tax assets - long term																	12
Indefinite intangible assets				190
Goodwill	357,022	363,888	732					16,607									105,331
Total assets acquired								65,977									349,981
Contingent supply liability																	5,891
Other																	731
Deferred tax liabilities - long term																	87,464
Accounts payable and other liabilities								5,910
Net assets acquired			$ 27,558					$ 60,067									$ 255,895	$ 255,895
Weighted average useful life						8 years	14 years			20 years		15 years	16 years		12 years	16 years			3 years	20 years

BUSINESS ACQUISITIONS - Schedule of Contingent Consideration (Details) (USD $) In Thousands, unless otherwise specified	6 Months Ended				6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015 Level 3 Potential Cash Consideration Fair Value	Dec. 31, 2014 Level 3 Potential Cash Consideration Fair Value	Jun. 30, 2015 Level 3 Selling, General and Administrative Expenses Potential Cash Consideration Fair Value
Business Acquisition, Contingent Consideration [Roll Forward]
Balance as of January 1, 2015			$ 22,247	$ 22,008
Loss from increase in fair value of contingent consideration liabilities	239	(998)			239
Fair value at June 30, 2015			$ 22,247	$ 22,008

BUSINESS ACQUISITIONS - Pro Forma Information (Details) (USD $) In Thousands, except Per Share data, unless otherwise specified	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Business Acquisition [Line Items]
Total revenue	$ 241,801	$ 467,310
Net income	$ 7,009	$ 12,581
Basic (in dollars per share)	$ 0.22	$ 0.39

INVENTORIES (Inventory, Net) (Details) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2015	Dec. 31, 2014
Inventory, Net [Abstract]
Finished goods	$ 146,912	$ 150,483
Work-in process	54,707	50,166
Raw materials	40,216	36,465
Inventories, net	$ 241,835	$ 237,114

- Definition

Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.

+ References+ Details

GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Goodwill (Details) (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Goodwill [Roll Forward]
Goodwill at December 31, 2014		$ 363,888
Balance, June 30, 2015	357,022	363,888
Orthopedics and Tissue Technologies
Goodwill [Line Items]
Goodwill, gross		81,650
Accumulated impairment losses		0
Goodwill [Roll Forward]
Goodwill at December 31, 2014	81,650
Goodwill impairment charge	0
Foreign currency translation	(1,441)
Balance, June 30, 2015	80,472
Spine
Goodwill [Line Items]
Goodwill, gross		409
Accumulated impairment losses		0
Goodwill [Roll Forward]
Goodwill at December 31, 2014	409
Goodwill impairment charge	(409)
Foreign currency translation	0
Balance, June 30, 2015	0
U.S. Spine And Other
Goodwill [Line Items]
Goodwill, gross		363,888
Accumulated impairment losses		0
Goodwill [Roll Forward]
Goodwill at December 31, 2014	363,888
Goodwill impairment charge	(409)
Foreign currency translation	(5,892)
Balance, June 30, 2015	357,022
Specialty Surgical Solutions
Goodwill [Line Items]
Goodwill, gross		281,829
Accumulated impairment losses		0
Goodwill [Roll Forward]
Goodwill at December 31, 2014	281,829
Goodwill impairment charge	0
Foreign currency translation	(4,451)
Balance, June 30, 2015	276,550
Medtronic MicroFrance
Goodwill [Roll Forward]
Balance, June 30, 2015	16,607
Medtronic MicroFrance \| Orthopedics and Tissue Technologies
Goodwill [Roll Forward]
Working capital and purchase price adjustment	0
Medtronic MicroFrance \| Spine
Goodwill [Roll Forward]
Working capital and purchase price adjustment	0
Medtronic MicroFrance \| U.S. Spine And Other
Goodwill [Roll Forward]
Working capital and purchase price adjustment	(828)
Medtronic MicroFrance \| Specialty Surgical Solutions
Goodwill [Roll Forward]
Working capital and purchase price adjustment	(828)
Metasurg
Goodwill [Roll Forward]
Balance, June 30, 2015	732
Metasurg \| Orthopedics and Tissue Technologies
Goodwill [Roll Forward]
Working capital and purchase price adjustment	263
Metasurg \| Spine
Goodwill [Roll Forward]
Working capital and purchase price adjustment	0
Metasurg \| U.S. Spine And Other
Goodwill [Roll Forward]
Working capital and purchase price adjustment	263
Metasurg \| Specialty Surgical Solutions
Goodwill [Roll Forward]
Working capital and purchase price adjustment	$ 0

GOODWILL AND OTHER INTANGIBLE ASSETS - Components of Company's Identifiable Intangible Assets (Details) (USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Acquired Finite-Lived Intangible Assets [Line Items]
Cost	$ 633,101,000	$ 639,648,000
Accumulated Amortization	(192,518,000)	(180,189,000)
Net	440,583,000	459,459,000
Completed technology
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted Average Life	18 years	18 years
Cost	344,406,000	345,082,000
Accumulated Amortization	(72,393,000)	(62,920,000)
Net	272,013,000	282,162,000
Customer relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted Average Life	12 years	12 years
Cost	159,548,000	162,031,000
Accumulated Amortization	(91,621,000)	(87,653,000)
Net	67,927,000	74,378,000
Trademarks/brand names
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted Average Life	34 years	34 years
Cost	43,221,000	44,520,000
Accumulated Amortization	(15,814,000)	(15,755,000)
Net	27,407,000	28,765,000
Trademarks/brand names indefinite
Acquired Finite-Lived Intangible Assets [Line Items]
Cost	48,484,000	48,484,000
Accumulated Amortization	0	0
Net	48,484,000	48,484,000
Supplier relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted Average Life	27 years	27 years
Cost	34,721,000	34,721,000
Accumulated Amortization	(11,522,000)	(10,809,000)
Net	23,199,000	23,912,000
All other
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted Average Life	4 years	4 years
Cost	2,721,000	4,810,000
Accumulated Amortization	(1,168,000)	(3,052,000)
Net	1,553,000	1,758,000
In Process Research and Development
Acquired Finite-Lived Intangible Assets [Line Items]
Other Indefinite-lived Intangible Assets	$ 1,400,000	$ 1,400,000

GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) (USD $)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Goodwill [Line Items]
Impairment of intangible assets	$ 409,000	$ 600,000
Annual amortization expense expected to approximate in 2015	31,900,000
Annual amortization expense expected to approximate in 2016	29,700,000
Annual amortization expense expected to approximate in 2017	27,600,000
Annual amortization expense expected to approximate in 2018	27,300,000
Annual amortization expense expected to approximate in 2019	26,500,000
Confluent Surgical, Inc.
Goodwill [Line Items]
Impairment of intangible assets	$ 600,000

DEBT -Narrative (Details) (USD $)	6 Months Ended			0 Months Ended		0 Months Ended			0 Months Ended							0 Months Ended				0 Months Ended		0 Months Ended
DEBT -Narrative (Details) (USD $)	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Jul. 02, 2014 July 2014 Amendment	Jul. 02, 2014 July 2014 Amendment	Jul. 02, 2014 July 2014 Amendment Minimum	Jul. 02, 2014 July 2014 Amendment Maximum	Jul. 02, 2014 July 2014 Amendment Standby Letters of Credit	Jul. 02, 2014 July 2014 Amendment Revolving Credit Facility	Jul. 02, 2014 July 2014 Amendment Revolving Credit Facility	Jul. 02, 2014 July 2014 Amendment Swingline Loan	Jun. 30, 2015 Term Loan	Jul. 02, 2014 June 2011 Amendment Revolving Credit Facility	Jun. 30, 2015 Revolving Credit Facility	Dec. 31, 2014 Revolving Credit Facility	Jun. 15, 2011 2016 Convertible Senior Notes	Jun. 30, 2015 2016 Convertible Senior Notes	Jun. 16, 2015 2016 Convertible Senior Notes convertible_debt_instrument	Dec. 31, 2014 2016 Convertible Senior Notes	Jul. 02, 2014 Term Loan July 2014 Amendment	Jul. 02, 2014 Term Loan July 2014 Amendment	Jul. 02, 2014 Federal Funds July 2014 Amendment	Jul. 02, 2014 (LIBOR) July 2014 Amendment	Jul. 02, 2014 Eurodollar July 2014 Amendment Minimum	Jul. 02, 2014 Eurodollar July 2014 Amendment Maximum
Debt Instrument [Line Items]
Senior credit facility, maximum borrowing capacity					$ 900,000,000			$ 60,000,000		$ 750,000,000	$ 60,000,000		$ 600,000,000								$ 150,000,000
Additional commitments					200,000,000
Interest rates available to the Company at its option																						0.50%	1.00%	1.00%	1.75%
Cash balance threshold above which excess amount is not subject to any restriction of use or investment					40,000,000
Line of credit, commitment fee percentage						0.15%	0.30%
Deferred finance costs, gross					3,200,000
Amortization of debt issuance costs	1,060,000	1,243,000		300,000
Proceeds from lines of credit							422,000,000		272,000,000											150,000,000
Line of credit facility outstanding														286,900,000	266,900,000
Weighted average interest rate on debt												1.80%		2.00%	1.70%
Available borrowings under senior secured revolving credit facility														463,100,000
Term loan, amount outstanding	150,000,000
Line of credit facility, fair value of amount outstanding														269,100,000
Long-term debt, fair value												143,000,000
Principal amount outstanding																230,000,000	230,000,000		230,000,000
Interest rate on debt																1.625%
Portion of the debt proceeds that was classified as equity at the time of the offering																43,200,000
Effective interest rate implicit in the liability component																5.60%
Carrying amount of liability	214,358,000		213,121,000														217,300,000		213,100,000
Unamortized discount																	12,700,000		16,900,000
Fair value of outstanding borrowings																	285,800,000
Common stock based on initial conversion rate ratio (in shares)																17.4092
Principal amount to be considered for conversion purpose																1,000
Initial conversion price, per share																$ 57.44
Maximum selling price of company's common stock																150.00%
Principal amount of notes per average trading price																$ 1,000
Maximum average conversion value of the Notes																98.00%
Number debt instruments pending conversion																		2,903
Strike price of the call transaction (in dollars per share)																$ 57.44
Strike price of warrant transactions (in dollars per share)																$ 70.05

DEBT -5 year payout table (Details) (Term Loan, USD $) In Thousands, unless otherwise specified	Jun. 30, 2015
Term Loan
Term loan maturities [Line Items]
Long-term Debt, Maturities, Repayments of Principal in 2015	$ 3,750
Long-term Debt, Maturities, Repayments of Principal in 2016	9,375
Long-term Debt, Maturities, Repayments of Principal in 2017	13,125
Long-term Debt, Maturities, Repayments of Principal in 2018	15,000
Long-term Debt, Maturities, Repayments of Principal in 2019	108,750
Secured Debt	$ 150,000

DEBT - Components of Interest Expense (Detail) (2016 Convertible Senior Notes, USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
2016 Convertible Senior Notes
Debt Instrument [Line Items]
Amortization of the discount on the liability component	$ 1,885	$ 1,766	$ 3,744	$ 3,433
Cash interest related to the contractual interest coupon	824	837	1,669	1,639
Total	$ 2,709	$ 2,603	$ 5,413	$ 5,072

DERIVATIVE INSTRUMENTS - Narrative (Detail) (USD $)	6 Months Ended
DERIVATIVE INSTRUMENTS - Narrative (Detail) (USD $)	Jun. 30, 2015	Jun. 30, 2014
Derivative [Line Items]
Interest rate swap expiration date	August 10, 2015
Gain (loss) on hedging ineffectiveness	$ 0	$ 0
Interest Rate Swap
Derivative [Line Items]
Pretax losses expected to be reclassified from AOCI in next 12 months	$ 200,000
Foreign Exchange Contract
Derivative [Line Items]
Derivative contracts	0

DERIVATIVE INSTRUMENTS - Summary of Fair Value in Balance Sheet for Derivatives Designated Hedging Instruments (Detail) (USD $)	6 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Derivative Instruments and Hedging Activities Disclosure [Line Items]
Fair value of derivative liabilities	$ 161,000	$ 898,000
Interest Rate Swap
Derivative Instruments and Hedging Activities Disclosure [Line Items]
Notional amount derivative instruments	90,000,000	97,500,000
Reduction in notional amount of interest rate derivatives in next twelve months	90,000,000
Interest Rate Swap \| Accrued expenses and other current liabilities
Derivative Instruments and Hedging Activities Disclosure [Line Items]
Fair value of derivative liabilities	$ 161,000	$ 898,000

DERIVATIVE INSTRUMENTS - Effect of Derivative Instruments Designated Cash Flow Hedges on Statements of Operations (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Derivative Instruments, Gain (Loss) [Line Items]
Balance in AOCI Beginning of Period	$ (527)	$ (2,097)	$ (898)	$ (2,439)
Amount of Loss Recognized in AOCI- Effective Portion	(7)	(60)	(25)	(169)
Amount of Loss Reclassified from AOCI into Earnings-Effective Portion	(373)	(444)	(762)	(895)
Balance in AOCI End of Period	(161)	(1,713)	(161)	(1,713)
Interest Expense \| Interest Rate Swap
Derivative Instruments, Gain (Loss) [Line Items]
Balance in AOCI Beginning of Period	(527)	(2,097)	(898)	(2,439)
Amount of Loss Recognized in AOCI- Effective Portion	(7)	(60)	(25)	(169)
Amount of Loss Reclassified from AOCI into Earnings-Effective Portion	(373)	(444)	(762)	(895)
Balance in AOCI End of Period	$ (161)	$ (1,713)	$ (161)	$ (1,713)

STOCK-BASED COMPENSATION - Narrative (Detail) (USD $) In Millions, except Share data, unless otherwise specified	6 Months Ended
	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grants in period, net of forfeitures	77,347
Requisite service periods of awards, in years	3 years
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options exercisable, vesting period, in years	4 years
Total unrecognized compensation costs	$ 2.4
Weighted-average period for cost recognition, in years	2 years
Restricted stock awards/stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options exercisable, vesting period, in years	3 years
Total unrecognized compensation costs	$ 18.4
Weighted-average period for cost recognition, in years	2 years
Awards granted during period	146,300
Performance shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards granted during period	64,930
Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period, in years	8 years
Directors and certain executive officers \| Minimum \| Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period, in years	8 years
Directors and certain executive officers \| Maximum \| Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period, in years	10 years

TREASURY STOCK (Additional Information) (Detail) (USD $)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Oct. 28, 2014 October 2012 Authorization
Accelerated Share Repurchases [Line Items]
Stock repurchase program, authorized amount			$ 75,000,000
Stock repurchased during period, shares	0	0
Amount available for share repurchase under this latest authorization	$ 75,000,000

INCOME TAXES - Narrative (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Tax Disclosure [Abstract]
Reported tax rate	34.00%	32.90%	33.70%	37.00%
Nondeductible spinoff expense	$ 0.4
Income Tax Contingency [Line Items]
Effective Tax Rate Estimate			32.00%
Foreign Tax Authority
Income Tax Contingency [Line Items]
Change in tax expense due to filing with tax authorities	0.4
Change in tax expense due to settlement with tax authority			1.1
State and Local Jurisdiction
Income Tax Contingency [Line Items]
Change in tax expense due to change in filing position			$ 0.3

INCOME TAXES - Summary of Effective Tax Rate (Detail)	3 Months Ended		6 Months Ended
INCOME TAXES - Summary of Effective Tax Rate (Detail)	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Tax Disclosure [Abstract]
Reported tax rate	34.00%	32.90%	33.70%	37.00%

NET INCOME PER SHARE - Narrative (Detail) In Millions, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Stock options, shares outstanding (in shares)	1.1	1.4	1.4
Stock Compensation Plan
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares excluded from computation as their effect would be anti-dilutive	0.1	0.2	0.2

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References+ Details

NET INCOME PER SHARE - Basic and Diluted Net Income Per Share (Detail) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Basic net income per share:
Net income	$ 4,998	$ 4,825	$ 13,382	$ 7,031
Weighted average common shares outstanding (in shares)	33,032	32,398	32,884	32,336
Basic net income per common share (in dollars per share)	$ 0.15	$ 0.15	$ 0.41	$ 0.22
Diluted net income per share:
Net income	$ 4,998	$ 4,825	$ 13,382	$ 7,031
Weighted average common shares outstanding (in shares)	33,032	32,398	32,884	32,336
Effect of dilutive securities:
2016 Convertible notes (in shares)	477	0	268	0
Stock options and restricted stock (in shares)	430	406	492	460
Weighted average common shares for diluted earnings per share (in shares)	33,939	32,804	33,644	32,796
Diluted net income per common share (in dollars per share)	$ 0.15	$ 0.15	$ 0.40	$ 0.21

COMPREHENSIVE INCOME (LOSS) - Schedule of Comprehensive Loss Income (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Equity [Abstract]
Net income	$ 4,998	$ 4,825	$ 13,382	$ 7,031
Foreign currency translation adjustment	7,166	(234)	(17,227)	585
Change in unrealized gain on derivatives, net of tax	209	219	420	414
Pension liability adjustment, net of tax	(48)	(58)	7	(73)
Comprehensive income (loss)	$ 12,325	$ 4,752	$ (3,418)	$ 7,957

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References+ Details

- Definition

Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.

+ References+ Details

- Definition

Amount after tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).

+ References+ Details

COMPREHENSIVE INCOME (LOSS) (Schedule of Changes in Accumulated Other Comprehensive Income by Component (Details) (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2015
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	$ (23,488)
Other comprehensive (loss) income before reclassifications	(17,234)
Amounts reclassified from accumulated other comprehensive income	434
Net current-period other comprehensive income (loss)	(16,800)
Ending balance	(40,288)
Gains and Losses on Cash Flow Hedges
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	(512)
Other comprehensive (loss) income before reclassifications	(14)
Amounts reclassified from accumulated other comprehensive income	434
Net current-period other comprehensive income (loss)	420
Ending balance	(92)
Defined Benefit Pension Items
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	(906)
Other comprehensive (loss) income before reclassifications	7
Amounts reclassified from accumulated other comprehensive income	0
Net current-period other comprehensive income (loss)	7
Ending balance	(899)
Foreign Currency Items
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	(22,070)
Other comprehensive (loss) income before reclassifications	(17,227)
Amounts reclassified from accumulated other comprehensive income	0
Net current-period other comprehensive income (loss)	(17,227)
Ending balance	$ (39,297)

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References+ Details

COMPREHENSIVE INCOME (LOSS) (Reclassification Adjustment from AOCI) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Interest (expense)	$ (5,471)	$ (5,382)	$ (10,963)	$ (10,524)
Tax (expense) or benefit	(2,574)	(2,361)	(6,807)	(4,130)
Net income	4,998	4,825	13,382	7,031
Reclassification out of Accumulated Other Comprehensive Income \| Gains and Losses on Cash Flow Hedges
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Tax (expense) or benefit	160		327
Net income	(213)		(434)
Reclassification out of Accumulated Other Comprehensive Income \| Gains and Losses on Cash Flow Hedges \| Interest Rate Swap
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Interest (expense)	$ (373)		$ (761)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References+ Details

SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Detail)	6 Months Ended
SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Detail)	Jun. 30, 2015 Segment
Segment Reporting [Abstract]
Number of reportable segments	3
Specialty Surgical Solutions
Segment Reporting Information [Line Items]
Number of products offered	60,000

SEGMENT AND GEOGRAPHIC INFORMATION - Net Sales and Profit by Reportable Segment (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Segment Reporting Information [Line Items]
Revenues	$ 244,078	$ 231,351	$ 477,743	$ 446,410
Operating income	13,954	12,392	30,742	21,130
Intangible asset amortization	(3,104)	(2,985)	(6,639)	(6,018)
Operating Segments
Segment Reporting Information [Line Items]
Operating income	82,019	73,111	162,245	141,157
Operating Segments \| Specialty Surgical Solutions
Segment Reporting Information [Line Items]
Revenues	146,709	137,516	125,199	112,544
Operating income	62,325	48,991	38,010	37,020
Operating Segments \| Orthopedics and Tissue Technologies
Segment Reporting Information [Line Items]
Revenues	63,834	57,954	286,769	264,710
Operating income	18,428	20,019	122,657	97,288
Operating Segments \| Spine
Segment Reporting Information [Line Items]
Revenues	33,535	35,881	65,775	69,156
Operating income	1,266	4,101	1,578	6,849
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Operating income	$ (64,961)	$ (57,734)	$ (124,864)	$ (114,009)

SEGMENT AND GEOGRAPHIC INFORMATION - Total Revenue by Major Geographic Area (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Segment Reporting Information [Line Items]
Revenues	$ 244,078	$ 231,351	$ 477,743	$ 446,410
United States
Segment Reporting Information [Line Items]
Revenues	190,093	178,806	371,030	342,187
Europe
Segment Reporting Information [Line Items]
Revenues	27,497	25,851	54,258	51,176
Rest of World
Segment Reporting Information [Line Items]
Revenues	$ 26,488	$ 26,694	$ 52,455	$ 53,047

SUBSEQUENT EVENTS - Narrative (Details) (USD $)	0 Months Ended					0 Months Ended						0 Months Ended
SUBSEQUENT EVENTS - Narrative (Details) (USD $)	Jul. 17, 2015 Subsequent Event acquisition	Jul. 02, 2015 Subsequent Event	Jul. 17, 2015 TEI Biosciences Inc. Subsequent Event	Jul. 17, 2015 TEI Medical Inc. Subsequent Event	Jul. 17, 2015 TEI Biosciences Inc and TEI Medical Inc. Subsequent Event case	Jun. 15, 2011 2016 Convertible Senior Notes	Jul. 02, 2015 2016 Convertible Senior Notes Subsequent Event	Jul. 02, 2014 July 2014 Amendment Revolving Credit Facility	Jul. 17, 2015 July 2014 Amendment Revolving Credit Facility Subsequent Event	Jul. 17, 2015 Indemnification period - Up to 15 months after close TEI Biosciences Inc and TEI Medical Inc. Subsequent Event	Jul. 17, 2015 Indemnification period - Up to 15 months after close TEI Biosciences Inc and TEI Medical Inc. Subsequent Event	Jul. 17, 2015 Indemnification period - Up to 3 years after close TEI Biosciences Inc and TEI Medical Inc. Subsequent Event	Jul. 17, 2015 Indemnification period - Up to 3 years after close TEI Biosciences Inc and TEI Medical Inc. Subsequent Event
Subsequent Event [Line Items]
Distribution of shares, percent		100.00%
Shares of Integra required for share of Sea Spine		3
Initial conversion price, per share						$ 57.44	$ 52.83
Common stock based on initial conversion rate ratio (in shares)						17.4092	18.9287
Strike price of the call transaction (in dollars per share)						$ 57.44	$ 52.83
Strike price of warrant transactions (in dollars per share)						$ 70.05	$ 64.43
Number of businesses acquired	2
Consideration for acquisition	$ 312,000,000		$ 211,000,000	$ 101,000,000
Proceeds from lines of credit								272,000,000	310,000,000
Number of active cases					45
Indemnification policy in place					3,000,000.0
Maximum indemnification from acquisition											30,000,000.0		30,000,000.0
Period of indemnification										15 months		3 years
Minimum indemnification from acquisition													$ 20,000,000.0

TREASURY STOCK	6 Months Ended
TREASURY STOCK	Jun. 30, 2015
Treasury Stock Transactions, Excluding Value of Shares Reissued [Abstract]
TREASURY STOCK	TREASURY STOCK On October 28, 2014, the Board of Directors terminated the October 2012 authorization and authorized up to $75.0 million of its outstanding common stock through December 2016. The Company has not repurchased any of its outstanding shares of common stock during the six-month periods ended June 30, 2015 and 2014. As of June 30, 2015, there remained $75.0 million available for repurchases under this authorization.